{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:49:49Z","timestamp":1789145389421,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004543","name":"China Scholarship Council","doi-asserted-by":"crossref","award":["CSC2022062320370"],"award-info":[{"award-number":["CSC2022062320370"]}],"id":[{"id":"10.13039\/501100004543","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Econ Rev"],"DOI":"10.1186\/s13561-025-00611-0","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T06:57:51Z","timestamp":1742021871000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-effectiveness analysis of combination therapies involving novel agents for first\/second-relapse patients with multiple myeloma: a Markov model approach with calibration techniques"],"prefix":"10.1186","volume":"15","author":[{"given":"Weijia","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyuan","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqianzi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengjin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"issue":"9","key":"611_CR1","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, et al. Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol. 2018;4(9):1221\u20137.","journal-title":"JAMA Oncol"},{"key":"611_CR2","doi-asserted-by":"publisher","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","volume":"28","author":"A Palumbo","year":"2010","unstructured":"Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol. 2010;28:5101\u20139.","journal-title":"J Clin Oncol"},{"key":"611_CR3","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"M Cavo","year":"2010","unstructured":"Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomized phase 3 study. Lancet. 2010;376:2075\u201385.","journal-title":"Lancet"},{"key":"611_CR4","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","volume":"32","author":"M Roussel","year":"2014","unstructured":"Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du My\u00e9lome. J Clin Oncol. 2014;32:2712\u20137.","journal-title":"J Clin Oncol"},{"issue":"1","key":"611_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(21)00579-9","volume":"23","author":"SZ Usmani","year":"2022","unstructured":"Usmani SZ, Quach H, Mateos MV, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomized, multicenter, open-label, phase 3 study. Lancet Oncol. 2022;23(1):65\u201376.","journal-title":"Lancet Oncol"},{"issue":"14","key":"611_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319\u201331.","journal-title":"N Engl J Med"},{"issue":"8","key":"611_CR7","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754\u201366.","journal-title":"N Engl J Med"},{"issue":"7","key":"611_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373(7):621\u201331.","journal-title":"N Engl J Med"},{"issue":"8","key":"611_CR9","first-page":"1600","volume":"41","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld P, Chanan-Khan A, Weisel K, et al. Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label. Phase III Trial J Clin Oncol. 2023;41(8):1600\u20139.","journal-title":"Phase III Trial J Clin Oncol"},{"issue":"14","key":"611_CR10","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1182\/bloodadvances.2023010026","volume":"7","author":"SZ Usmani","year":"2023","unstructured":"Usmani SZ, Quach H, Mateos MV, et al. Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. Blood Adv. 2023;7(14):3739\u201348.","journal-title":"Blood Adv"},{"issue":"9","key":"611_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41408-020-00357-4","volume":"10","author":"MA Dimopoulos","year":"2020","unstructured":"Dimopoulos MA, Lonial S, White D, et al. Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study. Blood Cancer J. 2020;10(9):91. https:\/\/doi.org\/10.1038\/s41408-020-00357-4. Published 2020 Sep 4.","journal-title":"Blood Cancer J"},{"issue":"24","key":"611_CR12","doi-asserted-by":"publisher","first-page":"2757","DOI":"10.1182\/blood-2016-09-692947","volume":"128","author":"SV Rajkumar","year":"2016","unstructured":"Rajkumar SV, Harousseau JL. Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. Blood. 2016;128(24):2757\u201364.","journal-title":"Blood"},{"issue":"2","key":"611_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-021-00431-5","volume":"11","author":"R Fonseca","year":"2021","unstructured":"Fonseca R, Hagiwara M, Panjabi S, Yucel E, Buchanan J, Delea T. Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US. Blood Cancer J. 2021;11(2):35.","journal-title":"Blood Cancer J"},{"issue":"4","key":"611_CR14","first-page":"204","volume":"8","author":"A Roy","year":"2015","unstructured":"Roy A, Kish JK, Bloudek L, et al. Estimating the costs of therapy in patients with relapsed and\/or refractory multiple myeloma: a model framework. Am Health Drug Benefits. 2015;8(4):204\u201315.","journal-title":"Am Health Drug Benefits"},{"issue":"7","key":"611_CR15","doi-asserted-by":"publisher","first-page":"e2116357","DOI":"10.1001\/jamanetworkopen.2021.16357","volume":"4","author":"K Bhattacharya","year":"2021","unstructured":"Bhattacharya K, Bentley JP, Ramachandran S, et al. Phase-specific and lifetime costs of multiple myeloma among older adults in the US. JAMA Netw Open. 2021;4(7):e2116357.","journal-title":"JAMA Netw Open"},{"key":"611_CR16","unstructured":"Financial burden of cancer care. National Cancer Institute cancer trends progress report. US. https:\/\/progressreport.cancer.gov\/after\/economic_burden."},{"key":"611_CR17","unstructured":"J Lu, J Wang, L Yang. Analysis of direct medical expenses of multiple myeloma patients in China. Chin J Pharm Econ. 2020;16(06):18 \u2013 23+30. (Chinese)."},{"issue":"11","key":"611_CR18","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1080\/10428194.2021.1933477","volume":"62","author":"KK Patel","year":"2021","unstructured":"Patel KK, Parker T, Di M, Bar N, Huntington SF, Giri S. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leuk Lymphoma. 2021;62(11):2777\u201384.","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"611_CR19","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1200\/JCO.20.01849","volume":"39","author":"KK Patel","year":"2021","unstructured":"Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-effectiveness of first-line versus second-line use of daratumumab in older, transplant-ineligible patients with multiple myeloma. J Clin Oncol. 2021;39(10):1119\u201328.","journal-title":"J Clin Oncol"},{"issue":"11","key":"611_CR20","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s40273-021-01068-9","volume":"39","author":"M Dolph","year":"2021","unstructured":"Dolph M, Tremblay G, Leong H. Cost effectiveness of triplet selinexor-bortezomib-dexamethasone (XVd) in previously treated Multiple Myeloma (MM) based on results from the phase III BOSTON Trial. Pharmacoeconomics. 2021;39(11):1309\u201325. https:\/\/doi.org\/10.1007\/s40273-021-01068-9.","journal-title":"Pharmacoeconomics"},{"key":"611_CR21","unstructured":"Canada\u2019s Health Technology Agency. An economic evaluation was performed to assess the cost-effectiveness of various treatment sequences for patients 3 with multiple myeloma (MM) who are transplant-ineligible. https:\/\/www.cadth.ca\/sites\/default\/files\/2023-11\/TR0014%20Pharmacoeconomic%20Report%20Draft%20for%20Stakeholder%20Feedback%20November%2002.pdf."},{"key":"611_CR22","unstructured":"NICE. Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib. https:\/\/www.nice.org.uk\/guidance\/ta586."},{"issue":"2","key":"611_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1080\/14737167.2022.2017285","volume":"22","author":"XY Wong","year":"2022","unstructured":"Wong XY, Chng WJ, Aziz MIA, Ng K. Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and\/or refractory multiple myeloma. Expert Rev Pharmacoecon Outcomes Res. 2022;22(2):207\u201315. https:\/\/doi.org\/10.1080\/14737167.2022.2017285. (Epub 2021 Dec 22 PMID: 34904498).","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"611_CR24","doi-asserted-by":"publisher","unstructured":"Chinese Medical Doctor Association, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of multiple myeloma (2024 version). Chin J Internal Med. 2024,63(12):1186\u201395. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20240928-00616.","DOI":"10.3760\/cma.j.cn112138-20240928-00616"},{"issue":"12","key":"611_CR25","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","volume":"18","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Callander NS, Adekola K, et al. Multiple myeloma, version 3.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2020;18(12):1685\u2013717.","journal-title":"J Natl Compr Canc Netw"},{"issue":"10262","key":"611_CR26","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","volume":"396","author":"S Grosicki","year":"2020","unstructured":"Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563\u201373.","journal-title":"Lancet"},{"issue":"6","key":"611_CR27","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781\u201394.","journal-title":"Lancet Oncol"},{"key":"611_CR28","doi-asserted-by":"publisher","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27\u201338. https:\/\/doi.org\/10.1016\/S1470-2045(15)00464-7.","DOI":"10.1016\/S1470-2045(15)00464-7"},{"issue":"11","key":"611_CR29","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel JF, Hungria VT, Yoon SS, et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicenter, randomized, double-blind phase 3 trial. Lancet Oncol. 2014;15(11):1195\u2013206.","journal-title":"Lancet Oncol"},{"issue":"2","key":"611_CR30","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372(2):142\u201352.","journal-title":"N Engl J Med"},{"issue":"17","key":"611_CR31","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374(17):1621\u201334.","journal-title":"N Engl J Med"},{"issue":"22","key":"611_CR32","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1200\/JCO.21.00972","volume":"39","author":"PG Richardson","year":"2021","unstructured":"Richardson PG, Kumar SK, Masszi T, et al. Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2021;39(22):2430\u201342.","journal-title":"J Clin Oncol"},{"issue":"10292","key":"611_CR33","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/S0140-6736(21)00592-4","volume":"397","author":"P Moreau","year":"2021","unstructured":"Moreau P, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicenter, open-label, randomized phase 3 trial. Lancet. 2021;397(10292):2361\u201371.","journal-title":"Lancet"},{"issue":"1","key":"611_CR34","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-023-00797-8","volume":"13","author":"T Martin","year":"2023","unstructured":"Martin T, Dimopoulos MA, Mikhael J, et al. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study. Blood Cancer J. 2023;13(1):72.","journal-title":"Blood Cancer J"},{"key":"611_CR35","unstructured":"National Health Commission of People\u2019s Republic of China, China. China Health Statistics Yearbook. 2022. Accessed at: http:\/\/www.nhc.gov.cn\/mohwsbwstjxxzx\/tjtjnj\/202305\/6ef68aac6bd14c1eb9375e01a0faa1fb.shtml."},{"issue":"3","key":"611_CR36","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","volume":"36","author":"M Binder","year":"2022","unstructured":"Binder M, Nandakumar B, Rajkumar SV, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36(3):801\u20138.","journal-title":"Leukemia"},{"issue":"1","key":"611_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41408-023-00785-y","volume":"13","author":"U Goel","year":"2023","unstructured":"Goel U, Charalampous C, Kapoor P, et al. Defining drug\/drug class refractoriness vs lines of therapy in relapsed\/refractory multiple myeloma. Blood Cancer J. 2023;13(1):11 Published 2023 Jan 11.","journal-title":"Blood Cancer J"},{"key":"611_CR38","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2147\/CEOR.S305830","volume":"13","author":"M Dolph","year":"2021","unstructured":"Dolph M, Tremblay G, Leong H. US budget impact model for selinexor, bortezomib, and dexamethasone for the treatment of previously treated multiple myeloma. Clinicoecon Outcomes Res. 2021;13:493\u2013502.","journal-title":"Clinicoecon Outcomes Res"},{"key":"611_CR39","unstructured":"National Institute for Health and Care Excellence, UK. Single technology appraisal: ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]. 2022. https:\/\/www.nice.org.uk\/guidance\/ta505."},{"issue":"3","key":"611_CR40","doi-asserted-by":"publisher","first-page":"e026309","DOI":"10.1136\/bmjopen-2018-026309","volume":"9","author":"Z Li","year":"2019","unstructured":"Li Z, Pan Z, Zhang L, et al. End-of-life cost and its determinants for cancer patients in urban China: a population-based retrospective study. BMJ Open. 2019;9(3):e026309.","journal-title":"BMJ Open"},{"key":"611_CR41","doi-asserted-by":"crossref","unstructured":"Herdman M, Gudex C, Lloyd A, et al. Development and preliminary testing of an official five-level version of EQ-5D. EQ-5D Group, Rotterdam. 2009.","DOI":"10.1016\/S1098-3015(10)74095-X"},{"issue":"4","key":"611_CR42","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.jval.2016.11.016","volume":"20","author":"N Luo","year":"2017","unstructured":"Luo N, Liu G, Li M, et al. Estimating an EQ-5D-5L value set for China. Value Health. 2017;20(4):662\u20139.","journal-title":"Value Health"},{"issue":"1","key":"611_CR43","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/heapol\/czw096","volume":"32","author":"LA Robinson","year":"2017","unstructured":"Robinson LA, Hammitt JK, Chang AY, et al. Understanding and improving the one- and three-times GDP per capita cost-effectiveness thresholds. Health Policy Plan. 2017;32(1):141\u20135.","journal-title":"Health Policy Plan"},{"issue":"32","key":"611_CR44","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.1200\/JCO.2018.79.0642","volume":"36","author":"JK Lin","year":"2018","unstructured":"Lin JK, Lerman BJ, Barnes JI, et al. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol. 2018;36(32):3192\u2013202. https:\/\/doi.org\/10.1200\/JCO.2018.79.0642.","journal-title":"J Clin Oncol"},{"issue":"30","key":"611_CR45","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Gay F, Cavallo F, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015;33(30):3459\u201366. https:\/\/doi.org\/10.1200\/JCO.2014.60.2466.","journal-title":"J Clin Oncol"},{"key":"611_CR46","unstructured":"Latimer, N. NICE DSU technical support document 14: undertaking survival analysis for economic evaluations alongside clinical trials - extrapolation with patient-level data. 2011. Available from http:\/\/www.nicedsu.org.uk."},{"key":"611_CR47","unstructured":"Sen W, Jie J. Evaluation the value of daratumumab for the treatment of patients with relapse or refractory multiple myeloma. Jinan University, 2019. Master's degree thesis in Chinese. Accessed at: https:\/\/www.cqvip.com\/doc\/degree\/2416938301?sign=47ea077f6a33f1bad5a970f7a8cf23a9957719a1f3a13c7eb506670ae2151fee&expireTime=1741933224388&resourceId=2416938301."},{"key":"611_CR48","unstructured":"Q Jiang, J Han, Y Zheng. Cost-effectiveness analysis of daratumumab, bortezomib and dexamethasone in Chinese patients with relapse or refractory multiple myeloma. J Trop Med. 2022;22(01):91\u201394+106+145."}],"container-title":["Health Economics Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-025-00611-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13561-025-00611-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13561-025-00611-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T06:57:58Z","timestamp":1742021878000},"score":1,"resource":{"primary":{"URL":"https:\/\/healtheconomicsreview.biomedcentral.com\/articles\/10.1186\/s13561-025-00611-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1186\/s13561-025-00611-0","relation":{},"ISSN":["2191-1991"],"issn-type":[{"value":"2191-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research, involving the collection of cost and health utility data in MM patients, was approved by the Institutional Review Board of the School of Public Health, Zhejiang University (ZGL202008-1) and conducted in accordance with the Declaration of Helsinki.\u00a0Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}